IF WISHES WERE VACCINES…
BioSpectrum Asia|June 2020
The long road till commercial availability compelling sustained funding at unprecedented levels. Combined with the $ 2 billion outlay expected from GAVI / CEPI and various government institutions and alliances across the globe, the total economic interest invested in this research would be at a never-before-seen or imagined level.
Manasee Kurlekar
IF WISHES WERE VACCINES…

One of the most obvious positive fallout of this COVID-19 pandemic has been the tremendous increase in focus on, and funding for, vaccines. When COVID-19 first broke out in China in December 2019, the number of influenza vaccines under research and discovery were about 15. At that level, this was still higher by several times compared to two decades ago.

Vaccines have traditionally always lagged behind drug discovery as a favoured area of research for the pharma and biotech sector as a whole. The reasons are many, starting from the time and investment needed for the research and discovery. Before the COVID-19 pandemic and current feverish pace of the race to find the vaccine against it, the 2015 ZIKA vaccine held the record for the shortest time taken from initiation to completion of trials – seven months. Add to this the cumbersome process of production which would take years to produce sufficient doses for the affected populations: the ZIKA pandemic had already fizzled out before large scale commercial production could be achieved.

This leads to the most critical economic aspect of the process - the uncertainty surrounding the final take-up of the vaccine by populations. It is not surprising therefore that the funding for them has grown primarily through sources from government institutions like BARDA and charity outfits like the Bill and Melinda Gates Foundation, via the critical role executed by organisations like Coalition for Epidemic Preparedness Innovations (CEPI) and GAVI (Global Alliance for Vaccines and Immunisation), the vaccine alliance.

This story is from the June 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the June 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024
Why Singapore is Deep Tech Innovation Frontrunner
BioSpectrum Asia

Why Singapore is Deep Tech Innovation Frontrunner

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

time-read
4 mins  |
March 2024
Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?
BioSpectrum Asia

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

The World Health Organization (WHO) has taken a significant stride in the battle against Tuberculosis (TB) by introducing shorter drug regimens, aiming to curb a disease that claims countless lives globally. This innovative approach addresses the urgent need for more efficient treatments, especially in regions where TB's toll is highest. With traditional therapies often posing risks to liver health, these shortened regimens offer hope, minimising such concerns while enhancing treatment adherence.

time-read
5 mins  |
March 2024
How pharma is finally researching issues that primarily affect women
BioSpectrum Asia

How pharma is finally researching issues that primarily affect women

Pharma is now concentrating on problems that impact women. Female participation will now directly contribute to cures for diseases that affect them, since more studies specifically targeted at women are planned.

time-read
8 mins  |
March 2024
Championing PAY PARITY
BioSpectrum Asia

Championing PAY PARITY

Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.

time-read
6 mins  |
March 2024
ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
BioSpectrum Asia

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

Globally, women constitute 46 per cent of the workforce in the public sector, whereas in the private sector, they represent 33 per cent. The public sector maintains a higher representation of women as employees compared to the private sector as per data from the World Bank.

time-read
10+ mins  |
March 2024
US FDA approves first medication to treat severe frostbite
BioSpectrum Asia

US FDA approves first medication to treat severe frostbite

The US Food and Drug Administration (FDA) has approved Eicos Sciences Inc’s Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

time-read
1 min  |
March 2024
Japanese startup RevolKa to create highly functional proteins by using AI-driven platform
BioSpectrum Asia

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

RevolKa, a venture-backed biotech startup providing a gamechanging protein engineering technology platform, based in Japan, has signed a contract research agreement with Sekisui Chemical.

time-read
1 min  |
March 2024
Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development
BioSpectrum Asia

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

Taiwan-based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

time-read
1 min  |
March 2024
Samsung Biologics & LegoChem Biosciences team up for ADC development
BioSpectrum Asia

Samsung Biologics & LegoChem Biosciences team up for ADC development

South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has signed a partnership agreement with LegoChem Biosciences, a Korean biotech company pioneering the research and development of antibody-drug conjugate (ADC) programmes.

time-read
1 min  |
March 2024